- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00151021
Stepping Up to Health: Feedback to Promote Physical Activity in Diabetes
Automated Step-count Feedback to Promote Physical Activity in Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective #1: To develop and test a computer program that automatically collects enhanced pedometer data, records the data in a format suitable for statistical analysis, and generates a personally tailored motivational web page and distributes an e-mail reminder message to encourage the participant to log on to his/her website.
Objective #2: To compare total daily steps in people with diabetes randomized to two different 6-week pedometer and web-based walking interventions. The two interventions will differ only in the emphasis for goal setting and feedback.
Group 1: Emphasizes 10-minute minimum duration of physical activity bouts
Group 2: Emphasizes total daily steps without regard to duration of walking bouts
Objective #3: To compare steps accumulated in walking bouts lasting for at least 10 minutes between the same two groups of participants with diabetes.
Objective #4: To assess the feasibility, cost, dropout rate and participant satisfaction with a pedometer and web-based walking intervention for participants with diabetes.
This study will consist of three phases. Phase I will be the development of a web-based interactive system including data downloading and tailored messages.
Phase II is a usability testing phase in which 8 participants will be recruited to wear the pedometer, interact with the web-based system and give feedback for final development. The Usability phase will occur exactly like the Phase III outlined below except that the participants will be assigned to a study group rather than randomized, and they will be on-study for 2 weeks only - one week for the enrollment phase and one week of the intervention phase. At the end of the intervention week, they will not complete the post survey but will instead complete a feasibility/usability survey and meet with the study staff to help define improvements and adjustments for the Phase III trial. To maximize the Usability Phase, the feedback received from the first four participants will be incorporated in the website before the last four participants are enrolled.
The final phase (Phase III) will include a total of 40 men and women ages > 18 years old, who have Type II Diabetes and are interested in starting a walking program. If they meet eligibility and sign a consent form they will enroll in a randomized control trial comparing two similar interventions to promote walking. Both interventions are 6-week pedometer-based interventions that rely on step-count feedback to motivate participants to increase their walking. Tailored behavioral, informational and motivational messages will be delivered on the website and the enhanced pedometer work by participants will automatically upload time-stamped step count data to a central computer. One of the interventions, the "10 minute bouts" intervention will emphasize bouts of walking lasting at least 10 minutes and of at least moderate intensity. The second intervention called the "total steps" intervention will emphasize total accumulated daily step counts without regard to duration or intensity of walking bouts.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan, Department of Family Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Have type 2 diabetes
- Have a sedentary lifestyle
- Interested in starting a walking program
- Regular computer users who check e-mail at least 5 times a week and have access to a personal computer (PC) with XP or Windows 2000 operating system, 128 MB of memory, and an available universal serial bus (USB) port.
- Can identify a primary care doctor, endocrinologist or cardiologist and obtain written clearance to start a walking program.
- Willing to provide written informed consent
- Can communicate in English
Exclusion Criteria:
- Used a pedometer in past 30 days
- Currently pregnant
- Cannot comfortably walk at least one block
- Cannot obtain written clearance to start a walking program from primary care doctor, endocrinologist or cardiologist
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Step-count bout ratio = 7 day average of steps taken during 10 minute bouts in one day divided by total steps taken during the same day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Caroline R Richardson, MD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDRTC 5P60DKK20572
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Tailored web-based walking program
-
Henry Ford Health SystemUniversity of Michigan; Augusta University; Children's Hospital of MichiganCompletedAcute AsthmaUnited States
-
National Cancer Center, KoreaSamsung Medical Center; Seoul National University Hospital; Korea University...UnknownCancer-related FatigueKorea, Republic of
-
Georgetown UniversityAlbert Einstein College of Medicine; University of MichiganCompletedTobacco Cessation | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Virus, Human Immunodeficiency | Tobacco-Use DisorderUnited States
-
Henry Ford Health SystemNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Physical Activity | Sleep | Communication | NutritionUnited States
-
University Medical Center GroningenCompleted
-
Robert Wood Johnson FoundationKaiser PermanenteCompleted
-
Agency for Healthcare Research and Quality (AHRQ)UnknownWell Child Preventive CareUnited States
-
VA Office of Research and DevelopmentNot yet recruitingPeripheral Artery DiseaseUnited States
-
Queen's University, BelfastAXA PPP HealthcareCompleted